Business
Opus Genetics Announces Financial Results for Full Year 2024
Provides update on the Company’s transformation and promising portfolio of innovative gene therapy treatments for inherited retinal diseases Strong cash position with $21.5 million financing to supplement $30.3 million year-end balance New capital supports delivery on key milestones for two lead gene therapy candidates OPGx-LCA5 and OPGx-BEST1 RESEARCH TRIANGLE PARK, N.C., March 31, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (“Opus” or the “Company”) (Nasdaq: IRD), a clinical-stage ophthalmic
About this update from Opus Genetics, Inc.
[{"type":"image","alt":"Opus Genetics, Inc.","displaySize":"","headline":null,"caption":"Opus Genetics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":129,"url":"https://media.zenfs.com/en/globenewswire.com/5903b8b33116d080342bdaf2c6a1b0bd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xl5Pbyep4pXJ5VZR6DH1.Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5903b8b33116d080342bdaf2c6a1b0bd","width":300,"height":129}},"lazy":false},{"type":"text","content":"Provides update on the Company’s transformation and promising portfolio of innovative gene therapy treatments for inherited retinal diseases","length":140,"tagName":"p"},{"type":"text","content":"Strong cash position with $21.5 million financing to supplement $30.3 million year-end balance","length":94,"tagName":"p"},{"type":"text","content":"New capital supports delivery on key milestones for two lead gene therapy candidates OPGx-LCA5 and OPGx-BEST1","length":109,"tagName":"p"},{"type":"text","content":"RESEARCH TRIANGLE PARK, N.C., March 31, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (“Opus” or the “Company”) (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing important new therapies for the treatment of inherited retinal diseases (IRDs) and other ophthalmic disorders, today announced financial results for the full year ended December 31, 2024, and provided a corporate update.","length":411,"tagName":"p"},{"type":"text","content":"“2024 marked a year of significant progress and change for the Company,” said George Magrath, M.D., Chief Executive Officer. “We began the year with an uncertain future, with a lead asset that had failed to meet its primary endpoints in Phase 2 and another asset that had been fully out-licensed for commercialization. Given this portfolio, we took decisive action to position the Company to build additional value. Our transformative acquisition of privately held Opus Genetics in October strengthens our pipeline with a promising portfolio of gene therapy assets.”","length":566,"tagName":"p"},{"type":"text","content":"“2025 is shaping up to be another exciting year,” Dr. Magrath continued. “We recently completed a public offering and concurrent private placement, raising $21.5 million in capital primarily from leading institutional healthcare investors wh...